

## REFERENCES

### Thai

- พิมลวรรณ ทัญทุทพิจารณ์. การศึกษาความเป็นพิษเฉียบพลันของหญ้าปักกิ่งในหนูขาว. หนังสือรวบรวมผลงานการวิจัยโครงการพัฒนาการใช้สมุนไพรและยาไทยทางคลินิก ปี 2525-2526 : 197-203.
- พิมลวรรณ ทัญทุทพิจารณ์, เพียงจิต สัตตบุศย์, พรรณี พิเดช. พิษกึ่งเรื้อรังของหญ้าปักกิ่งในหนูขาว. สารศิริราช 2534; 43(8): 529-533.
- วีณา จิรัจฉริยากุล. สารต้านมะเร็งจากหญ้าปักกิ่ง. จุลสารข้อมูลสมุนไพร 16(ฉบับที่ 3) (2542): 10-13.
- วีณา จิรัจฉริยากุล และคณะ. การศึกษาหญ้าปักกิ่งด้านเภสัชวิทยาและองค์ประกอบเคมีเบื้องต้น. หนังสือรวบรวมผลงานการวิจัยโครงการพัฒนาการใช้สมุนไพรและยาไทยทางคลินิก ปี 2525-2536: 185-195.
- วีณา จิรัจฉริยากุล, พรทิพา พิชา. การศึกษาองค์ประกอบเคมีและความเป็นพิษต่อเซลล์ในหลอดทดลองของหญ้าปักกิ่ง. หนังสือรวบรวมผลงานการวิจัยโครงการพัฒนาการใช้สมุนไพรและยาไทยทางคลินิก ปี 2525-2536: 205-225.
- วีณา จิรัจฉริยากุล, เอมอร ไสมนะพันธ์ุ, มลวิภา วงษ์สกุล, ลีณา ลีลาศวัฒนกิจ, พรรณีภา ชุมศรี, ปัทมา สุนทรศารทูล. คุณสมบัติเป็นพิษต่อเซลล์ที่ผ่านทางระบบภูมิคุ้มกัน (ของคน) ของน้ำคั้นจากหญ้าปักกิ่ง (หญ้าเทวดา). กรุงเทพฯ: คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล; 2543.
- สาคร พรประเสริฐ, ขนิษฐา พันธุ์, อุษณีย์ วินิจเขตคำนวณ. ฤทธิ์ยับยั้งการแบ่งเซลล์และความเป็นพิษของหญ้าปักกิ่งต่อเซลล์มะเร็งเม็ดเลือดขาว. เชียงใหม่เวชสาร 40 (ฉบับที่4) (2544):195-203.
- สุภาภรณ์ ปิติพร, สุดใจ พรหมเกิด. หญ้าปักกิ่ง: สมุนไพรทางเลือกของผู้ป่วยมะเร็ง. กรุงเทพมหานคร: ชมรมหญ้าปักกิ่งต้านมะเร็ง; 2545.
- เอื้อพร ไชยวรรณ, สุวรรณา เวชอภิกุล, วิรัตน์ นิวัฒนนันท์, กนกพร นิวัฒนนันท์. การศึกษาฤทธิ์ลดระดับน้ำตาลในเลือดของส่วนสกัดจากหญ้าปักกิ่ง. เชียงใหม่: คณะเภสัชศาสตร์ มหาวิทยาลัยเชียงใหม่; 2544.

English

- Berthou, F. 2001. Cytochrome P450 enzyme regulation by induction and inhibition [Online]. Available from: <http://www.concytec.gob.pe/lecturas/berthou.pdf> [2003, Dec 1]
- Birkmayer, W., Riederer, P., Linauer, W., Knoll, J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm. 59 (1984): 81-87.
- Boone, C. W., Kelloff, G. J., Malone, W. E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res. 50 (1990): 2-9.
- Bouc, P. J. D., Lamprecht, J.H. Plant sterols and sterolins: A review of their immune-modulation properties. Altern Med Rev. 4(3) (1999): 170-177.
- Burke, M. D., Mayer, R. T. Ethoxyresorufin: Direct fluorometric assay of microsomal o-dealkylation which is preferentially induced by 3-methylcholanthrene. Drug Metab. Dispos. 2 (1974): 583-588.
- Christie, W. W. Mono- and digalactosyldiacylglycerols and related lipids from plants: structure, occurrence, biosynthesis and analysis [online]. 2002. Available from: <http://www.lipid.co.uk> [2004, Jan 5]
- Colic, M., Pavelic, K. Molecular mechanisms of anticancer activity of natural dietetic products. J Mol Med. 78(6) (2000): 333-336.
- Ferguson, L. R. Antimutagens as cancer chemopreventive agents in the diet. Mutat Res. 307(1) (1994): 395-410.
- Friedli, G. L. Structure/activity comparison in the ability of some terpenoid food flavors to cause peroxisome proliferation. Master of Science in Toxicology, University of Surrey, 1992.
- Gibson, G., Skett, P. Enzymology and molecular mechanisms of drug metabolism reactions. Introduction to drug metabolism 3<sup>th</sup> ed. pp. 35-76 New York: Chapman, 2000.

- Gonzalez, F. J., Gelboin, H. V. Role of human cytochrome P-450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26(1&2) (1994): 165-183.
- Guengerich, F. P. Human cytochrome P-450 enzymes. Life Science 50 (1992): 1471-1478.
- Guengerich, F. P. Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266(16) (1991): 10019-10022.
- Hayatsu, H., Arimoto, S., Negishi, T. Dietary inhibitors of mutagenesis and carcinogenesis. Mutat Res. 202(2) (1988): 429-446.
- Hood, R. D., editor. Handbook of developmental toxicology. Florida (FL): CRC Press; 1997.
- Intiyot, I., Kinouchi, T., Kataoka, K., Arimochi, H., Kuwahara, T., Vinitketkumnuen, U., Ohnishi, Y. Antimutagenicity of *Murdannia loriformis* in the *Salmonella* mutation assay and its inhibitory effects on azoxymethane induced DNA methylation and aberrant crypt focus formation in male F344 rats. J Med Invest. 49 (2002): 25-34.
- Jiratchariyakul, W., Moongkarndi, P., Okabe, H., Frahm, A. W. Investigation of anticancer components from *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. Pharma Indochina 20-23 May 1997. Faculty of Pharmacy, Mahidol Univ. Bangkok. Thailand.
- Jiratchariyakul, W., Okabe, H., Moongkarndi, P., Frahm, A. W. Cytotoxic glycosphingolipid from *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. Thai J Phytopharm. 51 (1998): 10-20.
- Jiratchariyakul, W., Soonthornchareonnon, N. Specifications of a Thai Medicinal Plant : *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy. Thai J Phytopharm. 2 (1995): 17-26.
- Kakizoe, T. Chemoprevention of cancer-Focus on clinical trials. Jpn J Clin Oncol. 33(9) (2003): 421-442.

- Kampa, M., *et al.* Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. Breast Cancer Res. 6 (2004): R63-R74.
- Lin, C. M., Chen, C. T., Lee, H. H., Lin, J. K. Prevention of cellular ROS damage by isovitexin and related flavonoids. Planta Med. 68 (2002): 365-367.
- Lin, J. H., Lu, A. Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 41 (2001): 535-567.
- Lind, C., Cadenas, E., Hochstein, P., Ernster, L. DT-diaphorase: purification, properties, and function. Methods in Enzymology 186 (1990): 287-301.
- Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951): 265-275.
- Lubet, R. A., Mayer, R. T., Cameron, J. W., Nim, R. W., Burke, M. D., Wolff, T., Guengerich, F. P. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238 (1985): 43-48.
- Mukherjee, S., Kumar, V., Prasad, A. K., *et al.* Synthetic and biological activity evaluation studies on novel 1,3-diarylpropenones. Bioorg. Med. Chem. 9 (2001): 337-345.
- Murray, R. K. Metabolism of xenobiotics. In Robert K., *et al* (eds): Harper's Biochemistry. Norwalk: Appleton & Lange; 1993.
- Narintorn, A. Phytochemical study of anticancer components from *Murdannia loriformis* (Hassk.) Rolla Rao et Kammathy [Master's thesis]. Bangkok: Graduate School, Mahidol University; 1999.
- Nash, T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. 55 (1953): 416-421.
- Oinomen, T., Lindros, K. O. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J. 329 (1998): 17-35.
- Omicinski, C. J., Rimmel, R. P., Hosagrahara, V. P. Concise review of the cytochrome P450s and their roles in toxicology. Toxicological Science. 48 (1999): 151-6.

- Omura, T., Sato, R. The carbonmonoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J. Biol. Chem. 239 (1964): 2370-2378.
- Parkinson, A. Biotransformation of xenobiotics. C.D. Klaassen, (ed.), Casarett & Doull's toxicology: The basic science of poisons 6<sup>th</sup> ed. pp.133-196. USA: McGraw-Hill, 2001.
- Percival, M. Phytonutrients & Detoxification. Clinical Nutrition Insights. 5(2) (1997): 1-4.
- Pereira, M. A., Barnes, L. H., Rassman, V. L., *et al.* Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15 (1994): 1049-1054.
- Potter, T. D., Coon, M. J. Cytochrome P-450, multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J. Biol. Chem. 266(21) (1991): 13469-13472.
- Ramel, C., Alekperov, U. K., Ames, B. N., Kada, T., Wattenberg, L. W. Inhibitors of mutagenesis and their relevance to carcinogenesis. Mutat Res. 168 (1986): 47-65.
- Rendic, S., Di Carlo, F. J. Human cytochrome P450 enzymes: Status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997): 413-580.
- Rice-Evans, C. A., editor. Flavonoids in health and disease. 2<sup>nd</sup> ed. London: Marcel Dekker, Inc., 2003.
- Riley, R. J., Workman, P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43 (1992): 1657-1669.
- Salalamp, P., Tamsiririrkul, R., Chuakul, W., *et al.* Medicinal Plants in Siri Ruckhachati Garden. Bangkok : Amarin Printing Group Co. Ltd., 1992.
- Satyanarayana, M., Tiwari, P., Tripathi, B. K., Srivastava, A. K., Pratap, R. Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. Bioorg. Med. Chem. 12 (2004): 1-7.
- Schenkman, J. B., Remmer, H., Estabrook, R. W. Spectral studies of drug interactions with hepatic microsomal cytochrome P-450. Mol. Pharmacol. 3 (1967): 113-123.

- Soucek, P., Gut, I. Cytochrome P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22(1) (1992): 83-103.
- Taavitsainen, P. Cytochrome isoform-specific in vitro methods to predict drug metabolism and interactions [Online]. Available from: <http://herkules.oulu.fi/isbn9514259009/isbn9514259009.pdf> [2004, Jan 7]
- The Rat Fan Club 2003. Normal Lab Values [online]. Available from: <http://www.ratfanclub.org/values.html> [2004, April 1]
- Timbrell, J., ed. Principles of biochemical toxicology 3<sup>rd</sup> ed. pp. 65-112. London: Taylor & Francis, 2000.
- Vinitketkumnun, U., Charoenkunathum, W., Kongtawelert, P., Lertprasertsuke, N., Picha, P., Matsushima, T. Antimutagenicity and DT-diaphorase inducer activity of the Thai medicinal plant, *Murdannia loriformis*. J Herbs Spices Med Plants. 41 (1996):45-52.
- Wattenberg, L. W. Inhibition of neoplasia by minor dietary constituents. Cancer Res. 43 (1983): 2448s-2453s.
- Weinstein, I. B. Cancer prevention: Recent progress and future opportunities. Cancer Res. 51(suppl) (1991): 5080-5085.
- Woolf, T. F., editor. Handbook of drug metabolism. New York (NY): Marcel Dekker; 1999.
- Wrighton, S. A., *et al.* Characterization of ethanol-inducible human liver N-nitrosodimethyl -amine demethylase. Biochemistry 22 (1986): 6731.
- Yamada, Y. *et al.*, Sequential analysis of morphological and biological properties of  $\beta$ -catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer research 61 (2001): 1874-1878.



APPENDICES

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

Table 8 Seven-day body weight of individual rat

Rat No.	day0	Day7	day14	Day21	day28
control					
1	288.8	324.8	358.5	373.8	385.9
2	312.4	342.5	361.9	378.5	397
3	313.3	368	403.8	423.9	424.7
4	335.6	383.7	402.3	413	419.4
5	352.2	372.3	374.4	397.3	401.8
6	328.9	339.8	355.3	362.7	366
7	392.5	402	425.4	444.6	467.8
8	415.5	431.7	460.7	466.9	478.3
9	399.2	415	393.7	426.1	443.5
10	419.9	445.3	431.2	459.5	468.3
ML-group I					
1	310.6	323.8	360.5	383.3	400.3
2	272.4	309.0	334.9	353.0	366.4
3	299.2	350.5	374.8	390.3	384.8
4	302.7	342.5	372.5	385.9	388.7
5	356.7	367.8	365.8	363.7	375.0
6	345.5	397.8	416.8	413.0	455.5
7	388.9	420.9	433.7	423.9	442.8
8	377.8	381.1	390.0	393.0	401.3
9	360.2	365.3	369.7	396.7	412.5
10	389.7	383.3	405.9	433.0	445.3
ML-group II					
1	292.6	311.7	340.5	364.3	384.8
2	267.4	321.5	365.2	391.0	424.9
3	309.3	355.5	389.8	409.3	406.7
4	345.9	401.0	445.5	464.3	474.2
5	371.9	395.3	411.3	416.9	432.7
6	334.5	379.8	396.3	388.4	415.9
7	386.5	386.1	396.3	398.2	423.8
8	436.0	449.3	479.1	491.8	509.8
9	406.7	416.7	409.9	432.0	439.0
10	372.8	370.7	391.6	397.6	404.3

Unit expressed as g



Table 9 Water consumption of individual rat

Rat No.	Day7	Day14	Day21	Day28
control				
1	42	43	34	38
2	56	36	35	28
3	63	53	45	51
4	48	49	47	53
5	60	56	47	55
6	62	96	54	55
7	61	34	45	38
8	38	45	38	12
9	71	47	40	38
10	47	39	40	38
ML-group I				
1	67	61	49	39
2	84	46	42	47
3	59	38	47	46
4	52	55	43	50
5	89	50	42	66
6	42	50	43	36
7	34	33	33	33
8	35	28	44	37
9	49	40	30	28
10	43	51	45	32
ML-group II				
1	67	61	49	39
2	84	46	42	47
3	59	38	47	46
4	52	55	43	50
5	89	50	42	66
6	42	50	43	36
7	34	33	33	33
8	35	28	44	37
9	49	40	30	28
10	43	51	45	32

Unit expressed as ml/day

Table 10 Food consumption of individual rat

Rat No.	Day7	Day14	Day21	Day28
control				
1	13	18	22	20
2	20	19	19	18
3	43	25	28	23
4	26	24	22	28
5	21	22	10	20
6	20	21	20	20
7	24	24	29	23
8	24	28	23	11
9	15	23	23	21
10	23	28	23	21
ML-group I				
1	32	22	22	23
2	33	25	20	15
3	33	28	29	26
4	28	41	23	31
5	22	33	13	22
6	35	36	24	26
7	23	23	28	23
8	23	16	24	24
9	30	25	23	22
10	23	35	20	18
ML-group II				
1	32	22	22	23
2	33	25	20	15
3	33	28	29	26
4	28	41	23	31
5	22	33	13	22
6	35	36	24	26
7	23	23	28	23
8	23	16	24	24
9	30	25	23	22
10	23	35	20	18

Unit expressed as g/day

**Table 11** Terminal body weight of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	380.50	384.50	370.20
2	380.90	350.70	396.70
3	439.70	407.00	421.30
4	409.20	382.30	465.00
5	392.10	356.80	417.30
6	349.40	438.10	397.90
7	446.70	430.10	408.00
8	461.80	387.00	487.40
9	417.20	405.70	434.80
10	457.40	438.60	401.60
Average	413.49	398.08	420.02
SEM	11.93	9.95	10.95

Unit expressed as g

**Table 12** Liver weight of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	10.51	12.01	11.60
2	10.36	10.14	11.61
3	16.66	15.36	14.96
4	11.85	11.00	14.95
5	9.71	11.74	14.71
6	10.98	14.86	11.26
7	14.08	12.66	12.05
8	14.00	13.21	14.67
9	13.18	13.30	16.12
10	16.44	13.72	12.24
Average	12.78	12.80	13.42
SEM	0.79	0.52	0.58

Unit expressed as g

Table 13 Serum AST concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
- 1	-	-	116
2	132	89	83
3	70	109	102
4	104	126	100
5	105	128	112
6	135	84	104
7	109	107	95
8	103	102	76
9	107	103	82
10	84	81	101
Average	105.44	103.22	97.10
SEM	6.79	5.59	4.15

Unit expressed as U/L

Table 14 Serum ALT concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	50	29
2	20	21	20
3	23	32	28
4	20	36	31
5	32	33	35
6	36	24	23
7	29	24	23
8	24	30	31
9	17	33	32
10	17	38	33
Average	24.22	32.10	28.50
SEM	2.25	2.65	1.57

Unit expressed as U/L

Table 15 Serum ALP concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
-1	-	108	107
2	101	120	107
3	199	266	225
4	95	114	118
5	99	117	119
6	118	127	119
7	107	107	134
8	101	100	126
9	111	125	135
10	116	166	112
Average	116.33	135.00	130.20
SEM	10.66	15.64	10.98

Unit expressed as U/L

Table 16 Serum total bilirubin concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	0.60	0.10
2	0.20	0.10	0.20
3	0.20	0.10	0.20
4	0.20	0.20	0.20
5	0.20	0.20	0.00
6	0.20	0.10	0.00
7	0.00	0.20	0.10
8	0.00	0.00	0.10
9	0.20	0.00	0.60
10	0.10	0.00	0.00
Average	0.14	0.15	0.15
SEM	0.03	0.06	0.06

Unit expressed as mg/dl

**Table 17** Serum direct bilirubin concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	0.40	0.00
2	0.00	0.00	0.10
3	0.10	0.10	0.10
4	0.10	0.10	0.10
5	0.10	0.10	0.00
6	0.00	0.00	0.00
7	0.00	0.00	0.10
8	0.00	0.00	0.10
9	0.20	0.00	0.60
10	0.10	0.00	0.00
Average	0.07	0.07	0.11
SEM	0.02	0.04	0.06

Unit expressed as mg/dl

**Table 18** BUN concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	21.80	20.50
2	18.60	15.40	20.90
3	29.60	26.80	28.30
4	20.00	18.70	17.60
5	16.80	17.50	18.10
6	22.10	15.80	13.70
7	16.50	17.80	16.50
8	18.10	17.80	14.60
9	20.60	25.00	17.40
10	20.50	23.80	29.10
Average	20.31	20.04	19.67
SEM	1.31	1.27	1.66

Unit expressed as mg/dl

Table 19 SCr concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	0.50	0.70
2	0.50	0.50	0.70
3	0.50	0.50	0.50
4	0.50	0.60	0.50
5	0.50	0.70	0.70
6	0.70	0.60	0.60
7	0.70	0.60	0.50
8	0.60	0.60	0.60
9	0.70	0.60	0.60
10	0.70	0.70	0.80
Average	0.60	0.59	0.62
SEM	0.03	0.02	0.03

Unit expressed as mg/dl

Table 20 Serum total cholesterol concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	100	64
2	61	63	59
3	75	75	92
4	92	57	86
5	57	57	61
6	60	68	50
7	58	59	59
8	68	63	59
9	72	71	100
10	85	96	69
Average	69.78	70.90	69.90
SEM	4.14	4.89	5.29

Unit expressed as mg/dl

Table 21 Serum LDL-C concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	5	4	5
3	5	7	10
4	14	3	3
5	7	7	5
6	5	5	4
7	5	5	4
8	4	7	5
9	8	6	-
10	8	8	8
Average	6.78	5.78	5.50
SEM	1.02	0.55	0.82

Unit expressed as mg/dl

Table 22 Serum HDL-C concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	42.10	32.40
2	27.00	30.20	27.80
3	41.60	47.20	57.30
4	36.70	28.90	43.80
5	24.20	27.40	31.20
6	31.30	34.30	23.30
7	28.10	31.50	30.10
8	29.60	30.70	31.60
9	34.00	35.40	50.50
10	40.70	55.10	35.20
Average	32.58	36.28	36.32
SEM	2.04	2.86	3.40

Unit expressed as mg/dl



**Table 23** Serum TG concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	80	101
2	88	119	134
3	131	77	107
4	53	106	122
5	60	52	98
6	110	118	109
7	83	103	105
8	134	80	135
9	85	158	-
10	118	150	94
Average	95.78	104.30	111.67
SEM	9.75	10.56	5.05

Unit expressed as mg/dl

**Table 24** Serum glucose concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	86	118	110
2	122	100	106
3	140	127	125
4	119	99	119
5	105	98	102
6	97	114	98
7	113	98	81
8	88	104	109
9	158	99	97
10	100	107	106
Average	112.80	106.40	105.30
SEM	7.24	3.19	3.85

Unit expressed as mg/dl

Table 25 Serum sodium concentration of individual rat

Rat No.	group		
	Control	MLgroup I	ML-group II
1	-	145	146
2	143	144	144
3	142	143	142
4	142	144	149
5	143	143	142
6	142	143	146
7	145	146	146
8	148	146	147
9	153	145	155
10	146	143	144
Average	144.89	144.20	146.10
SEM	1.23	0.39	1.21

Unit expressed as mEq/L

Table 26 Serum potassium concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	5.90	3.70
2	4.00	3.80	3.60
3	4.60	4.60	3.90
4	4.80	4.90	4.70
5	4.30	3.90	4.30
6	4.30	5.00	4.60
7	3.80	4.20	4.60
8	4.10	4.50	4.40
9	4.30	4.80	-
10	4.60	5.00	5.20
Average	4.31	4.66	4.33
SEM	0.11	0.20	0.17

Unit expressed as mEq/L

**Table 27** Serum chloride concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	111	106
2	104	106	104
3	102	103	104
4	105	106	110
5	103	103	104
6	105	104	106
7	105	104	106
8	107	107	105
9	113	105	114
10	104	104	105
Average	105.33	105.30	106.40
SEM	1.07	0.76	1.01

Unit expressed as mEq/L

**Table 28** Serum uric acid concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	3.00	2.10
2	1.80	1.60	1.30
3	2.00	1.60	1.70
4	2.00	1.90	1.70
5	1.90	2.20	1.50
6	1.90	2.00	1.90
7	1.70	1.80	1.70
8	1.90	1.50	1.80
9	2.20	1.50	1.20
10	2.70	1.90	1.80
Average	2.01	1.90	1.67
SEM	0.10	0.14	0.09

Unit expressed as mg/dl

Table 29 Hb of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	16.30	16.90	16.90
3	16.30	15.40	15.80
4	16.30	16.60	16.70
5	16.50	16.50	16.90
6	17.50	17.00	15.50
7	15.30	15.80	16.90
8	17.00	16.80	16.60
9	17.10	15.60	16.70
10	16.00	16.20	15.20
Average	16.48	16.31	16.36
SEM	0.22	0.20	0.22

Unit expressed as g/dl

Table 30 Hct of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	52	54	53
3	51	50	49
4	50	50	52
5	51	52	53
6	53	55	49
7	49	51	53
8	52	51	51
9	55	51	53
10	53	53	50
Average	51.78	51.89	51.44
SEM	0.60	0.59	0.58

Unit expressed as %

Table 31 Platelet count of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	719	764	814
3	699	766	591
4	912	684	736
5	674	724	674
6	712	938	792
7	666	750	716
8	934	886	806
9	852	748	680
10	626	710	658
Average	754.89	774.44	718.56
SEM	37.92	27.78	25.24

Unit expressed as  $\times 10^3$  cells /  $\text{mm}^3$

Table 32 WBC count of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	2220	1400	1050
3	1710	2390	2270
4	1854	1904	2100
5	1350	1980	1096
6	1636	2320	1224
7	1478	1324	1420
8	758	958	1774
9	1328	1096	512
10	488	1936	908
Average	1424.67	1700.89	1372.67
SEM	178.05	174.12	192.10

Unit expressed as cells /  $\text{mm}^3$

Table 33 Percent differential WBCs of individual rat

Rat No.	% differential WBCs				
	N	Eo	B	L	Mo
Control					
1	-	-	-	-	-
2	20	1	0	79	0
3	33	0	0	67	0
4	24	2	0	74	0
5	14	2	0	83	1
6	50	0	0	50	0
7	45	3	0	52	0
8	40	0	0	60	0
9	12	0	0	88	0
10	16	0	0	82	2
ML-group I					
1	-	-	-	-	-
2	44	0	0	55	1
3	35	1	0	64	0
4	13	1	0	85	1
5	18	0	0	80	2
6	55	0	0	44	1
7	54	0	0	46	0
8	22	0	0	77	1
9	19	0	0	80	1
10	25	0	0	75	0
ML-group II					
1	-	-	-	-	-
2	29	0	0	69	2
3	32	0	0	68	0
4	30	2	0	67	1
5	21	2	0	76	1
6	40	0	0	60	0
7	20	4	0	76	0
8	41	0	0	59	0
9	13	0	0	85	2
10	18	0	0	82	0

Unit expressed as %

N = neutrophil Eo = eosinophil B = basophil L = lymphocyte Mo = monocyte

Table 34 RBC count of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	8.92	9.14	8.68
3	9.20	8.98	8.54
4	8.72	8.56	9.20
5	9.14	9.50	9.42
6	9.24	9.26	8.58
7	8.50	9.20	9.10
8	9.02	9.16	8.96
9	9.86	9.34	9.18
10	8.98	8.94	8.54
Average	9.06	9.12	8.91
SEM	0.13	0.09	0.11

Unit expressed as  $\times 10^6$  cells /  $\text{mm}^3$

Table 35 RBC morphology of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	-	-	-
2	micro3+	micro3+	micro3+
3	micro2+	micro2+	micro2+
4	micro3+	micro3+	micro3+
5	micro3+	micro3+	micro3+
6	micro2+	micro2+	micro2+
7	micro2+	micro2+	micro2+
8	micro2+	micro2+	micro2+
9	micro3+	micro3+	micro3+
10	micro3+	micro3+	micro3+

Table 36 RBC indices (MCV, MCH and MCHC)

	MCV (fL)	MCH (pg)	MCHC (g/dL)
Control			
1	-	-	-
2	58.10	18.20	31.30
3	55.70	17.70	31.80
4	57.60	18.70	32.50
5	56.20	18.10	32.20
6	57.70	18.90	32.70
7	57.80	18.00	31.10
8	58.00	18.80	32.50
9	55.90	17.30	31.00
10	58.80	17.80	30.30
Mean $\pm$ SEM	57.31 $\pm$ 0.37	18.17 $\pm$ 0.18	31.71 $\pm$ 0.28
ML-group I			
1	-	-	-
2	59.30	18.50	31.20
3	55.10	17.20	31.10
4	58.00	19.40	33.50
5	54.50	17.40	31.90
6	59.10	18.40	31.10
7	55.80	17.20	30.90
8	56.00	18.40	32.80
9	54.40	16.70	30.60
10	59.40	18.20	30.60
Mean $\pm$ SEM	56.84 $\pm$ 0.70	17.93 $\pm$ 0.29	31.52 $\pm$ 0.34
ML-group II			
1	-	-	-
2	60.80	19.40	32.00
3	57.20	18.20	31.90
4	57.10	18.20	31.90
5	56.70	17.90	31.60
6	57.40	18.00	31.40
7	58.80	18.60	31.60
8	57.40	18.60	32.30
9	57.90	18.20	31.40
10	58.20	17.80	30.60
Mean $\pm$ SEM	57.94 $\pm$ 0.41	18.32 $\pm$ 0.16	31.63 $\pm$ 0.16



**Table 37** Microsomal protein concentration of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	31.46	21.24	10.42
2	23.95	26.02	21.36
3	40.43	29.75	36.90
4	37.73	28.30	38.04
5	27.47	22.30	25.87
6	28.47	28.41	30.43
7	33.57	26.43	33.30
8	32.27	27.50	29.23
9	33.14	34.55	36.39
10	38.35	34.88	35.53
Average	32.68	27.94	29.75
SEM	1.64	1.41	2.73

Unit expressed as mg/ml

**Table 38** Hepatic microsomal total CYP content of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	0.874	1.016	1.044
2	0.83	0.885	1.264
3	0.588	0.692	0.714
4	0.582	0.863	0.852
5	0.703	0.901	0.841
6	0.720	0.769	0.720
7	0.709	0.879	0.780
8	0.643	0.736	0.676
9	0.747	0.632	0.632
10	0.582	0.659	0.709
Average	0.698	0.803	0.823
SEM	0.032	0.039	0.062

Unit expressed as nmole/mg protein

**Table 39** Hepatic microsomal EROD activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	29	42	40
2	32	34	43
3	15	17	17
4	18	27	14
5	28	36	30
6	34	25	37
7	28	24	24
8	22	20	14
9	32	13	13
10	15	24	40
Average	25.30	26.20	27.20
SEM	2.29	2.82	3.87

Unit expressed as pmole/mg protein/min

**Table 40** Hepatic microsomal MROD activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	14	14	19
2	12	10	18
3	3	5	6
4	8	11	5
5	9	8	7
6	10	6	8
7	8	12	7
8	4	8	3
9	10	5	4
10	4	9	9
Average	8.20	8.80	8.60
SEM	1.14	0.95	1.75

Unit expressed as pmole/mg protein/min

**Table 41** Hepatic microsomal BROD activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	6	8	23
2	13	13	18
3	6	7	8
4	7	12	9
5	18	14	14
6	22	14	20
7	15	20	17
8	12	11	8
9	13	7	9
10	8	11	13
Average	12.00	11.70	13.90
SEM	1.70	1.25	1.72

Unit expressed as pmole/mg protein/min

**Table 42** Hepatic microsomal PROD activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	4	3	7
2	3	4	5
3	1	4	1
4	2	5	3
5	4	3	5
6	5	4	6
7	5	2	4
8	4	2	2
9	4	1	2
10	2	4	4
Average	3.40	3.20	3.90
SEM	0.43	0.39	0.61

Unit expressed as pmole/mg protein/min

**Table 43** Hepatic microsomal aniline 4-hydroxylase activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	0.117	0.102	0.146
2	0.117	0.130	0.110
3	0.026	0.027	0.017
4	0.029	0.071	0.037
5	0.103	0.155	0.106
6	0.125	0.033	0.087
7	0.117	0.099	0.068
8	0.084	0.094	0.076
9	0.103	0.063	0.096
10	0.046	0.020	0.099
Average	0.087	0.079	0.084
SEM	0.012	0.014	0.012

Unit expressed as nmole/mg protein/min


**Table 44** Hepatic microsomal erythromycin N-demethylase activity of individual rat

Rat No.	group		
	Control	ML-group I	ML-group II
1	0.842	1.244	1.161
2	0.940	0.999	0.936
3	1.156	1.171	1.151
4	0.823	1.205	1.009
5	0.945	0.857	0.872
6	1.024	1.102	0.828
7	0.764	0.882	0.808
8	1.043	0.950	0.779
9	1.185	1.107	0.891
10	0.960	1.200	1.053
Average	0.968	1.072	0.949
SEM	0.044	0.045	0.044

Unit expressed as nmole/mg protein/min


Table 45 Normal values of hematology and clinical blood chemistry parameters in rat (The Rat Fan Club, 2003).

Blood parameter	Normal values
AST (U/L)	77-110
ALT (U/L)	57-42
ALP (U/L)	104-160
Total bilirubin (mg/dl)	0.20-0.55
BUN (mg/dl)	15-21
SCr (mg/dl)	0.2-0.8
Total cholesterol (mg/dl)	55-88
Glucose (mg/dl)	50-135
Sodium (mEq/L)	143-156
Potassium (mEq/L)	4.6-5.9
Chloride (mEq/L)	100-110
Hb (g/dl)	10.0-16.7
Hct (%)	41.7-49.2
Platelet ( $\times 10^3$ cells / $\text{mm}^3$ )	685-1436
Neutrophil (%)	5.3-38.1
Eosinophil (%)	0-3.4
Basophil (%)	0-0.4
Lymphocyte (%)	56.7-93.1
Momocyte (%)	0-7.7
RBC ( $\times 10^6$ cells / $\text{mm}^3$ )	6.76-9.75
MCV (fL)	50.0-77.8
MVH (pg)	16.0-23.1
MCHC (g/dL)	28.2-34.1




**Figure 32** Verification of alkoxyresorufin O-dealkylation. Correlation between the amount of microsomal protein used in the reaction and fluorometric absorbance was shown with a correlation coefficient ( $r^2$ ) of 0.9992. Each point was mean of  $n=2$ . (Procedure was demonstrated in the Materials and Methods).

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 33** Verification of aniline 4-hydroxylation. Correlation between the amount of microsomal protein used in the reaction and absorbance was shown with a correlation coefficient ( $r^2$ ) of 0.9985. Each point was mean of  $n=2$ . (Procedure was demonstrated in the Materials and Methods).

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 34** Verification of erythromycin N-demethylation. Correlation between the amount of microsomal protein used in the reaction and absorbance was shown with a correlation coefficient ( $r^2$ ) of 1. Each point was mean of  $n=2$ . (Procedure was demonstrated in the Materials and Methods).

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย



## Study Protocol Approval

The Ethics Committee of the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand has approved the following study to be carried out according to the protocol dated and/ or amended as follows :

**Study Title** : SUBACUTE EFFECTS OF *MURDANNIA LORIFORMIS* EXTRACT ON HEPATIC CYTOCHROME P450 AND CLINICAL BLOOD CHEMISTRY IN RATS

**Study Code** : -


**Centre** : Chulalongkorn University


**Principal Investigator** : MISS ACHARA CHATSUPANG

**Protocol Date** : April 21, 2004

A list of the Ethics Committee members and positions present at the Ethics Committee meeting on the date of approval of this study has been attached.

This Study Protocol Approval Form will be forwarded to the Principal Investigator.

**Chairman of Ethics Committee** :   
(Boonyong Tantisira, Ph.D.)

**Secretary of Ethics Committee** :   
(Poj Kulvanich, Ph.D.)

**Date of Approval** : September 26, 2003

Figure 35 Study Protocol Approval by the Ethics Committee of the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok

## VITAE

Miss Achara Chatsupang was born in December 23, 1974 in Samutprakarn, Thailand. She graduated with a Bachelor of Sciences in Pharmacy in 1997 from the Faculty of Pharmaceutical Sciences, Mahidol University, Bangkok, Thailand. After graduation, she worked as a pharmacist in Bantak Hospital, Tak for one year and Samutprakarn Hospital for four years.



ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย